NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease

Blood

Volumn 130, Issue 5, 2017, Pages 606-618

  Mastaglio, Sara ^a   Genovese, Pietro ^b   Magnani, Zulma ^a   Ruggiero, Eliana ^a   Landoni, Elisa ^a   Camisa, Barbara ^a   Schiroli, Giulia ^b,c   Provasi, Elena ^a   Lombardo, Angelo ^b,c   Reik, Andreas ^d   Cieri, Nicoletta ^a   Rocchi, Martina ^a   Oliveira, Giacomo ^a   Escobar, Giulia ^b,c   Casucci, Monica ^a   Gentner, Bernhard ^a,b   Spinelli, Antonello ^a   Mondino, Anna ^a   Bondanza, Attilio ^a   Vago, Luca ^a   Ponzoni, Maurilio ^a,c   Ciceri, Fabio ^a,c   Holmes, Michael C ^d   Naldini, Luigi ^b,c   Bonini, Chiara ^a,c   more..

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d SANGAMO BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE FRAGMENT; PEPTIDE NY-ESO-1 157-165; TUMOR PROTEIN;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CELL SELECTION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EDITING; GENE TRANSFER; GENETIC MANIPULATION; GRAFT VERSUS HOST REACTION; HISTOLOGY; MEMORY T LYMPHOCYTE; MOUSE; MULTIPLE MYELOMA; MYELOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAFETY; SIGNAL TRANSDUCTION; STEM CELL; XENOGRAFT; ADOPTIVE TRANSFER; ANIMAL; DRUG SCREENING; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EDITING; GENE TRANSFER TECHNIQUES; GRAFT VS HOST DISEASE; IMMUNOLOGIC MEMORY; MICE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85026778095     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-08-732636     Document Type: Article

References (42)

1. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10): 2346-2357.
2. Schmitt TM, Aggen DH, Stromnes IM, et al. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood. 2013;122(3):348-356.
3. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015; 348(6230):69-74.
4. Alexandrov LB, Nik-Zainal S, Wedge DC, et al; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain. Signatures of mutational processes in human cancer [published correction appears in Nature. 2013;502(7470): 258]. Nature. 2013;500(7463):415-421.
5. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-129.
6. GM Bendle, C Linnemann, AI Hooijkaas, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010; 16(5):565-570.
7. Bleakley M, Turtle CJ, Riddell SR. Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2012;5(4): 409-425.
8. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674): 1550-1561.
9. Cieri N, Mastaglio S, Oliveira G, Casucci M, Bondanza A, Bonini C. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Immunol Rev. 2014;257(1):165-180.
10. Provasi E, Genovese P, Lombardo A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18(5):807-815.
11. Torikai H, Reik A, Liu PQ, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR [published correction appears in Blood. 2015;126(22):2527]. Blood. 2012; 119(24):5697-5705.
12. Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374):eaaj2013.
13. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8): 914-921.
14. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol. 2005; 174(7):4415-4423.
15. Chen JL, Dunbar PR, Gileadi U, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol. 2000;165(2):948-955.
16. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15(17):5323-5337.
17. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1-30.
18. Fujita S, Wada H, Jungbluth AA, et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res. 2004;10(19):6551-6558.
19. Nishikawa H, Maeda Y, Ishida T, et al. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/ lymphoma. Blood. 2012;119(13):3097-3104.
20. Nilsson M, Ljungberg J, Richter J, et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med. 2004;6(6): 631-641.
21. Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature. 2014; 510(7504):235-240.
22. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924.
23. Follenzi A, Naldini L. HIV-based vectors. Preparation and use. Methods Mol Med. 2002;69: 259-274.
24. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992; 257(5067):238-241.
25. Bondanza A, Hambach L, Aghai Z, et al. IL-7 receptor expression identifies suicide gene-modified allospecific CD81 T cells capable of self-renewal and differentiation into antileukemia effectors. Blood. 2011;117(24):6469-6478.
26. Bondanza A, Valtolina V, Magnani Z, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood. 2006;107(5):1828-1836.
27. Kaneko S, Mastaglio S, Bondanza A, et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood. 2009; 113(5):1006-1015.
28. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003;4(12):1191-1198.
29. Appay V, Dunbar PR, Callan M, et al. Memory CD81 T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8(4):379-385.
30. Huang J, Khong HT, Dudley ME, et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005;28(3):258-267.
31. Klebanoff CA, Gattinoni L, Restifo NP. CD81 T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211(1): 214-224.
32. Dolton G, Lissina A, Skowera A, et al. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells. Clin Exp Immunol. 2014;177(1):47-63.
33. Klippel ZK, Chou J, Towlerton AM, et al. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther. 2014;21(3):337-342.
34. Cieri N, Camisa B, Cocchiarella F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013; 121(4):573-584.
35. Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. Central memory self/tumor-reactive CD81 T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. 2005;102(27):9571-9576.
36. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754): 708-712.
37. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD81 T cells. J Clin Invest. 2005;115(6):1616-1626.
38. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD81 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118(1): 294-305.
39. Oliveira G, Ruggiero E, Stanghellini MT, et al. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory [published correction appears in Sci Transl Med. 2015;7(319): 319er9]. Sci Transl Med. 2015;7(317): 317ra198.
40. Robbins PF, Li YF, El-Gamil M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008;180(9):6116-6131.
41. Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood. 2016;127(25): 3117-3126.
42. Stadmauer EA. Cellular therapies or vaccines for myeloma. In: Proceedings from the American Society of Hematology; 3-6 December 2016; San Diego, CA.